"An analysis of CVS Health's Q2 2025 earnings report, which shows a significant financial rebound driven by strategic shifts, and what it means for the future."

Investing.com -- Formycon AG (ETR:FYB) reported first-half revenue of €9.0 million and an EBITDA loss of €17.9 million on Wednesday, while maintaining its full-year 2025 guidance. The German biosimilar developer continues to expect annual revenues between €55-65 million and an EBITDA loss of €10-20 million. Current market consensus estimates for the year stand at €54 million in revenue and a €19 million EBITDA loss, according to Factset data. Formycon reiterated its timeline for reaching positive EBITDA, which it expects "as early as 2026, but no later than 2027." The company’s first-half performance included €1.7 million in revenue from its share in the commercialization of FYB202/Otulfi, its Stelara biosimilar, which has been on the market for approximately four months in both the US and Europe. Management anticipates significantly stronger performance in the second half of 2025, with results particularly weighted toward the fourth quarter. This expected improvement is driven by two key factors: building momentum in the FYB202 launch later in the year, and the anticipated signing of a partnership deal for FYB206, its Keytruda biosimilar, which would likely include an upfront payment. The company’s outlook aligns with commentary from Sandoz (SIX:SDZ) regarding its own Stelara biosimilar, Pyzchiva, which also expects stronger performance later in the year. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.

YouTube video by Zacks Investment Awareness

Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.

The sale timing and amount will be determined by a variety of factors, including market prices.

Why Medtronic (MDT) is One of the Most Trusted Safe Dividend Stocks in Healthcare  Yahoo Finance

3 Top Medical Instruments Stocks Defying Tariff Pressure With GenAI  Zacks Investment Research

The busiest week we’ve seen in some time.  In fact, it’s so busy that I would venture to say that […]

What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks  The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential  Nasdaq

Most life sciences hedge funds, including Casdin Capital and Cormorant, are sinking deeper into the red.

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill  Nasdaq

By Danilo Masoni MILAN (Reuters) -Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies’ earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers’ shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We’ve moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. ’ARMAGEDDON SCENARIO’ Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we’re heading into an ’Armageddon scenario’, which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. CATALYST NEEDED Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors’ love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don’t like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn’t necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly (NYSE:LLY) and Merck (NSE:PROR) said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. "We’re seeing companies go from unprofitable to very profitable," he said, citing Alnylam and Penumbra (NYSE:PEN) as examples he owns. "Historically, that’s been a very good time to own healthcare stocks." LFG+ZEST’s Conca, who favours U.S. names like Abbott, Edwards Lifesciences (NYSE:EW), and AbbVie (NYSE:ABBV), along with Sanofi (NASDAQ:SNY) and Recordati (BIT:RECI) in Europe, said interest rate cuts could be a major catalyst. OUT OF THE WOODS? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk (NYSE:NVO) in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. "The sector will adapt," wrote Arnaud Cadart, healthcare analyst at France’s CIC Market Solutions. But that will come "at the cost of rebalancing its revenues and probably transforming its organisations." AstraZeneca (NASDAQ:AZN), for example, has unveiled a $50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. "Healthcare has endured a lot of pain," said J.P. Morgan’s Aliaga. "We’re not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been." With LLY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed LLY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including LLY, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is LLY poised for similar growth? Don't miss the opportunity to find out.